Qube Research & Technologies (QRT)
URGN icon

Qube Research & Technologies (QRT)’s UroGen Pharma URGN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-46,213
Closed -$427K – 3046
2023
Q1 		$427K Buy
46,213
+29,320
+174% +$270K ﹤0.01% 1611
2022
Q4 		$150K Buy
16,893
+3,604
+27% +$34.1K ﹤0.01% 1897
2022
Q3 		$111K Sell
13,289
-1,654
-11% -$13.7K ﹤0.01% 1946
2022
Q2 		$122K Buy
+14,943
New +$103K ﹤0.01% 1870

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Qube Research & Technologies (QRT)'s URGN Position: Q2 2023 in Review

Qube Research & Technologies (QRT) sold out of UroGen Pharma (URGN) in Q2 2023, closing a stake of 46,213 shares — an estimated $427K sold.

Qube Research & Technologies (QRT) first reported a position in URGN in Q2 2022 and held it in 4 quarters. The position peaked at $427K in Q1 2023. 85 funds tracked by Wall St. Rank hold URGN as of Q2 2023.

  • Qube Research & Technologies (QRT) reported no remaining UroGen Pharma position as of Q2 2023 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 46,213 UroGen Pharma shares in Q2 2023, an estimated $427K.
  • Qube Research & Technologies (QRT) first reported a position in UroGen Pharma in Q2 2022 and held it in 4 quarters.
  • Qube Research & Technologies (QRT)'s UroGen Pharma position peaked at $427K in Q1 2023.
  • 85 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2023.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2023, filed 14 Aug 2023.